Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

TVM Life Science Ventures VII Announces First Investment

Published: Tuesday, January 22, 2013
Last Updated: Tuesday, January 22, 2013
Bookmark and Share
TVM Life Science Ventures VII announced an investment into Kaneq Bioscience Ltd. based in Montreal, Quebec.

This company is a spin out of Kaneq Pharma Inc.

Kaneq Bioscience Ltd. was specifically created to develop a protein tyrosine phosphatase1B (“PTP-1B”) inhibitor for treating type 2 diabetes mellitus. “Other approaches targeting PTP-1B have shown efficacy in the clinic but oral small molecules have remained elusive. Our compound has promise as an orally active insulin sensitizer that can be paired with existing therapies.” stated Dr. Daniel Bouthillier, CEO of Kaneq Pharma Inc., who has joined Kaneq Bioscience Ltd. as Executive Chairman. Dr. Cynthia Lavoie, General Partner of TVM Capital Life Science and Board Member of Kaneq Bioscience Ltd. adds: “We are pleased to collaborate with Kaneq Pharma to create a company in Montreal which addresses a huge market need for diabetes patients”.

This is the first investment for TVM Life Science Ventures VII, a life sciences venture fund domiciled in Montreal QC, which follows a new investment approach to developing pharmaceutical assets to a human proof-of-concept in single asset companies. This approach has proven to be highly capital efficient through a high degree of outsourcing while creating an opportunity for faster exits through a trade sale to a pharmaceutical player looking to build its pipeline without having to take on legacy companies around the products that appeal to them.

Kaneq Bioscience Ltd. will tap into the rich ecosystem of service providers in the area to bring its asset to human proof-of-concept, including expertise provided by Montreal-based Chorus Canada, an offshoot of global-early-phase drug development network Chorus, an autonomous unit of Eli Lilly and Company. The company is also benefitting from the involvement of Kaneq Pharma management, a highly experienced team with complementary skills in pharmaceutical development.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Scientists Find Lethal Vulnerability in Treatment-Resistant Lung Cancer
The study describes how the drug Selinexor killed lung cancer cells and shrank tumors in mice when used against cancers driven by the aggressive and difficult-to-treat KRAS cancer gene.
Drug to Treat Alcohol Use Disorder Shows Promise Among Drinkers With High Stress
The findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress.
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!